Navigation Links
MSU scientists: Progesterone leads to inflammation
Date:8/19/2009

EAST LANSING, Mich. Scientists at Michigan State University have found exposure to the hormone progesterone activates genes that trigger inflammation in the mammary gland.

This progesterone-induced inflammation may be a key factor in increasing the risk of breast cancer.

Progesterone is a naturally occurring steroid hormone and promotes development of the normal mammary gland. Progesterone previously has been identified as a risk factor for breast cancer, and in a study published in the Journal of Steroid Biochemistry and Molecular Biology, MSU scientists examined the genes activated by progesterone and the effects of their activation in a mouse model system.

Exposure to progesterone in normal amounts and in normal circumstances causes inflammation, which promotes breast development. However, exposure to progesterone in menopausal hormone therapy is known to increase breast cancer risk.

"Progesterone turns on a wide array of genes involved in several biological processes, including cell adhesion, cell survival and inflammation," said physiology professor Sandra Haslam, co-author of the paper and director of the Breast Cancer and the Environment Research Center at MSU. "All of these processes may be relevant to the development of breast cancer."

The study shows progesterone significantly regulates 162 genes in pubertal cells, 104 genes in adult cells and 68 genes at both developmental stages. A number of these genes make small proteins, called chemokines, which control the process of inflammation.

Inflammation is a process where white blood cells move into a tissue. One type of white blood cell which moves to the breast during inflammation is a macrophage. Macrophages normally enter growing glands and help them develop, building blood vessels and reshaping growing tissue.

"Macrophages also may promote the development of tumors, such as breast cancer, as they make blood vessels to deliver nutrients and can clear the way for tumors to grow," Haslam said. "Long-term exposure to progesterone, such as that which occurs in menopausal hormone therapy, may encourage growth of tumors."

Haslam noted that as the link between progesterone and increased breast cancer risk was identified in recent years, women have been taking less hormone therapy after menopause and the rate of breast cancer in older women has gone down.

"This study reveals the targets of a specific form of the progesterone receptor, called PRA, in mammary cell development," said microbiology professor Richard Schwartz, a co-author of the paper and associate dean in the College of Natural Science. "The linkages identified provide targets for future work in reducing the influence progesterone has on developing breast cancer.

"Understanding the genes that regulate inflammation in the mammary gland will help us to better understand normal breast growth and also may help us devise better treatments for the abnormal growth in cancer."


'/>"/>

Contact: Jason Cody
codyja@msu.edu
517-432-0924
Michigan State University
Source:Eurekalert

Related medicine news :

1. Scientists: New technique identifies molecular biomarkers for disease
2. Emory researchers announce Phase III study of progesterone for traumatic brain injury
3. New Approach to Progesterone Supplementation in ART Revealed in Recently Published White Paper
4. Effectiveness of Progesterone in Reducing Preterm Births May Be Altered by Genetic Predisposition
5. Estrogen and progesterone receptor isoforms expression in the stomach of Mongolian gerbils
6. Progesterone Wont Shield Women Against Alzheimers
7. Vaginal progesterone gel may improve infant outcomes and...
8. Carnegie Mellon leads NSF initiative to develop modeling tools for disease and complex systems
9. Ten Years Later: O.I.S. Media Leads Physician Job Board Industry with Innovative Technology
10. LSTM leads project to develop HIV/AIDS strategy for Libya
11. Switch to digital mammography leads to increased cancer detection rates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... , ... Goodcents Deli Fresh Subs today announced the opening of a new ... St. Topeka, Kan. 66604 (near 21st and Gage). It is owned and operated by ... locations in the Topeka and Bonner Springs, Kan. area. , “Goodcents has such ...
(Date:6/23/2017)... ... June 23, 2017 , ... 21 Middle East and ... has selected 21 leaders from government, business and civil society in 11 countries across ... U.S. this fall, engaging in a transformative exchange of knowledge and ideas with the ...
(Date:6/23/2017)... ... , ... American Farmer, will feature Chr. Hansen, Inc (CHR Hansen) in an ... 2017. American Farmer airs Tuesdays at 8:30aET on RFD-TV. Check your local listings for ... Denmark in 1874 after a groundbreaking discovery of how to industrialize enzymes. Rooted in ...
(Date:6/23/2017)... TX (PRWEB) , ... June 23, 2017 , ... All-Star ... to residential and business clients throughout eastern Texas, is announcing the launch of a ... , Recent breast cancer statistics in the United States reveal that an estimated 252, ...
(Date:6/22/2017)... ... 22, 2017 , ... Plastic Surgery Associates is proud to report that founding ... year, research and information firm, Castle Connolly, releases their list of the most notable ... the 3rd time that Dr. Canales has been recognized by Castle Connolly. ...
Breaking Medicine News(10 mins):
(Date:6/19/2017)... , June 19, 2017  Researchers from DRUGSCAN ... that they will host a live, complimentary webinar titled, ... the benchtop to the real world" on Wednesday June ... This webinar will feature interviews with ... look into the manipulation techniques abusers use to prepare ...
(Date:6/14/2017)... June 14, 2017 The Bio Supply Management ... City of Fremont and the Biomedical Manufacturing ... industry in California by providing ... networking, and fostering workforce development. The primary focus of ... of start-ups, as well as small and mid-sized biomedical ...
(Date:6/11/2017)... June 10, 2017  Eli Lilly and Company (NYSE: ... Phase 3 studies of galcanezumab, an investigational treatment for ... data on several key secondary endpoints for galcanezumab compared ... these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented ... meeting in Boston . ...
Breaking Medicine Technology: